Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
Healthcare
$19.61 -2.48%
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
52W Low $8.98High $40.65
Volume 0.47M
Average 0.96M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$95.14M
FY 2025 · Annual
Investing Cash Flow
$72.46M
FY 2025 · Annual
Financing Cash Flow
$8.10M
FY 2025 · Annual
-96.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.89M | 10.59M | 13.53M | 22.8M | 28.01M |
| Change in Working Capital | (481K) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.49M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.97M) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Other Non-Cash Items | 3K | 3K | (1.25M) | (5.88M) | (2.12M) |
| Operating Cash Flow | (23.75M) | (50.29M) | (50.14M) | (69.77M) | (95.14M) |
| Capital Expenditures | (661K) | (559K) | (770K) | (664K) | (141K) |
| Acquisitions (Net) | 16K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (143.84M) | (263.62M) | (101.25M) |
| Sales of Investments | 0 | 0 | 0 | 165.89M | 173.86M |
| Other Investing Activities | 16 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (645K) | (559K) | (144.61M) | (98.4M) | 72.46M |
| Debt Repayment | (9K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 181.22M | 632K | 1.54M | 200M | 8.1M |
| Common Stock Repurchased | 0 | 0 | 0 | (420K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 514K | 0 | 0 | 2.56M | 0 |
| Financing Cash Flow | 311.35M | 632K | 1.54M | 202.14M | 8.1M |
| Effect of Forex Changes | 0 | (757K) | 0 | 0 | 0 |
| Net Change in Cash | 286.96M | (50.97M) | (193.21M) | 33.96M | (14.58M) |
| Free Cash Flow | (24.41M) | (50.84M) | (50.91M) | (70.44M) | (95.28M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$119.9M
+ D&A$546.0K
+ Stock-Based Comp$28.0M
+ Deferred Tax$0
- Working Capital-$1.6M
- Other Non-Cash-$2.1M
= Operating Cash Flow-$95.1M
- Capex-$141.0K
= Free Cash Flow-$95.3M
Analysis
FY2025 free cash flow is -$95.3M. FCF conversion is 79.4% of net income. Operating cash flow was -$95.1M, with capex of -$141.0K. The largest bridge item is Stock-Based Comp at $28.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| SC 13G | SC 13G filing | Sep 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 |
Does TYRA generate free cash flow?
Tyra Biosciences, Inc. (TYRA) generated -$95.28M of free cash flow in fiscal 2025.
How much operating cash flow does TYRA produce?
Operating cash flow was -$95.14M, before capital expenditures of $141,000.00.
Continue the stock analysis
Jump to another research area for this company.